Reality check folks!!! I went to my local (Spanish) public health lab in a small village, recently. It has been electronic for years. Go figure!!! http://lnkd.in/2cuTEi View in LinkedIn
Fantastic start and so much in the right direction. The first real key is mentoring these young entrepreneurs. The second real key is follow-on funding. We say "Mind The Gap" in the UK underground. The same applies to some of the businesses that will be seeded by these vital funds. The higher value enterprises, that will create a lot of jobs, will be facing The Gap as they mature, and it appears obvious that tax incentives for investments of this sort are critical. This includes keeping a healthy Venture Capital incentive alive and well. http://lnkd.in/--ct3d View in LinkedIn
Age is not the innovator. Ideas are. Always will be. but ideas are cheap. implementation is not. That said, there is truth in the fact that earlier in life entrepreneurs may be less encumbered with family and other ties. By contrast, the older entrepreneur, especially the successful" "serial entrepreneur is emerging as a sought-after asset by some very smart VCs. http://lnkd.in/NS_vQT View in LinkedIn
This appears to be a move that recognizes the power of personalized medicine -- reduced patient heterogeneity, or a 'zero phase' clinical trial for drug screening, obviating the sometimes misleading results from animal models. Also, implicitly, the possibility of growing donor organs in a test tube. Awesome! http://lnkd.in/CXkW8P View in LinkedIn
The fast emerging blurring of the lines between traditional VC's roles in funding emerging companies, and the saucy developments in crowd-funding is presented in this compelling article. While crowd-funding typically has funded near-to-market ventures, will it blur further south to pre-product promising discovery funding? That is the high risk high return sweet spot that young tech companies find the most challenging to finance. Watch thus space! http://lnkd.in/gPCsNB View in LinkedIn
Looking for orthopedic strategy experts to consult (in English by videoconferencing) for an innovative and easily implanted Pectus Excavatum device to treat the condition. The company gets the CE Mark this summer, and is evaluating all possible options for trials in the US, and elsewhere, with or without a partner, and a rollout plan fir Europe. Located close to Barcelona. View in LinkedIn
Taking advantage of the excellent research in the UK to further patient care is splendid. Let's hope that success breed success and more money is released. http://lnkd.in/eE98eb View in LinkedIn
After about five years of tough times fir funding biopharma, is this a glint of daylight spurred by recent liquidity? http://lnkd.in/Ytv3s4 View in LinkedIn
Further evidence that the strategy of Big Pharma may be shifting. While they have always had significant investments in Universities, this may be an uptick. Consider the fact that only 25 years ago in the UK and some Universities in the US, such close ties between industry and academia were considered odious, corrupting pure science. Welcome new world! http://lnkd.in/3U9Xwn View in LinkedIn
That emerging and small biopharma companies, or rather, their individual products, will be the future pipelines of big Pharma, appears inevitable. The nimble and efficient smaller companies can create new pharmaceutical" "Products more cheaply and quicker than their giant forerunners. The pattern may be emerging that the Skunk Work companies create, while the Big Guys market. This would be a happy outcome for everyone. http://lnkd.in/NytvX5 View in LinkedIn